T. Rowe Price Investment Management Portfolio holdings
T. Rowe Price Investment Management, Inc. (TRPIM), a division of T. Rowe Price Group established in August 2022 and headquartered in Baltimore, Maryland, is an active investment manager overseeing hundreds of billions in assets, focusing on equity and fixed-income strategies for institutional clients and sub-advisory mandates. Spun off from the parent company founded in 1937 by Thomas Rowe Price, Jr., TRPIM operates as a distinct entity with around 900 employees, emphasizing a research-driven, long-term approach rooted in fundamental analysis and disciplined risk management. Managing portfolios like large-cap growth and international equity funds, it complements T. Rowe Price’s broader offerings while targeting sophisticated investors such as pension funds and endowments with tailored, high-conviction solutions. Under the leadership of president Rob Sharps, TRPIM upholds the firm’s legacy of integrity and client focus, adapting its founder’s value-oriented philosophy to modern institutional needs.
Top Buys
| 1 |
Amazon
AMZN
|
$968M |
| 2 |
Starbucks
SBUX
|
$909M |
| 3 |
Hilton Worldwide
HLT
|
$698M |
| 4 |
NiSource
NI
|
$674M |
| 5 |
Becton Dickinson
BDX
|
$621M |
Top Sells
| 1 |
Fortive
FTV
|
$1.08B |
| 2 |
Marvell Technology
MRVL
|
$1.06B |
| 3 |
Thermo Fisher Scientific
TMO
|
$767M |
| 4 |
McKesson
MCK
|
$766M |
| 5 |
Broadcom
AVGO
|
$764M |
Sector Composition
| 1 | Technology | 29.18% |
| 2 | Healthcare | 18.36% |
| 3 | Consumer Discretionary | 13.25% |
| 4 | Industrials | 10.53% |
| 5 | Financials | 9.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
576
Zoetis
ZTS
$67.7B
| $6.01M | ﹤0.01% |
38,531
-10,455
| -21% | -$1.63M |
|
577
Applied Therapeutics
APLT
$76.2M
| $5.79M | ﹤0.01% |
18,683,990
+8,303,400
| +80% | +$2.57M |
|
578
Insight Enterprises
NSIT
$3.99B
| $5.62M | ﹤0.01% |
40,713
-286,286
| -88% | -$39.5M |
|
579
Icon
ICLR
$13.9B
| $5.43M | ﹤0.01% |
37,329
-52,086
| -58% | -$7.58M |
|
580
Boeing
BA
$180B
| $5.34M | ﹤0.01% |
25,500
-47,515
| -65% | -$9.96M |
|
581
argenx
ARGX
$42.8B
| $5.24M | ﹤0.01% |
9,510
-71,137
| -88% | -$39.2M |
|
582
IonQ
IONQ
$12.5B
| $5.19M | ﹤0.01% |
120,847
+40,126
| +50% | +$1.72M |
|
583
Tenet Healthcare
THC
$16.4B
| $4.1M | ﹤0.01% |
+23,300
| New | +$4.1M |
|
584
Tetra Tech
TTEK
$9.57B
| $3.98M | ﹤0.01% |
110,687
-8,818
| -7% | -$317K |
|
585
Kymera Therapeutics
KYMR
$2.87B
| $3.96M | ﹤0.01% |
+90,628
| New | +$3.96M |
|
586
Jasper Therapeutics
JSPR
$44.7M
| $3.91M | ﹤0.01% |
703,648
+891
| +0.1% | +$4.95K |
|
587
Eagle Bancorp
EGBN
$590M
| $3.55M | ﹤0.01% |
+182,260
| New | +$3.55M |
|
588
KLA
KLAC
$111B
| $3.42M | ﹤0.01% |
+3,821
| New | +$3.42M |
|
589
Karyopharm Therapeutics
KPTI
$58.6M
| $3.14M | ﹤0.01% |
728,766
+589,120
| +422% | +$2.54M |
|
590
Humana
HUM
$37B
| $3.1M | ﹤0.01% |
12,668
-154,902
| -92% | -$37.9M |
|
591
DT Midstream
DTM
$10.4B
| $2.77M | ﹤0.01% |
25,216
-187,646
| -88% | -$20.6M |
|
592
Robert Half
RHI
$3.81B
| $2.74M | ﹤0.01% |
66,610
-218,235
| -77% | -$8.96M |
|
593
Cadence Design Systems
CDNS
$93.1B
| $2.68M | ﹤0.01% |
8,699
-36,822
| -81% | -$11.3M |
|
594
Gilead Sciences
GILD
$140B
| $2.65M | ﹤0.01% |
+23,928
| New | +$2.65M |
|
595
Republic Services
RSG
$72.6B
| $2.47M | ﹤0.01% |
10,002
+1,871
| +23% | +$461K |
|
596
General Dynamics
GD
$86.8B
| $2.43M | ﹤0.01% |
8,318
+6,761
| +434% | +$1.97M |
|
597
Xenon Pharmaceuticals
XENE
$3.01B
| $2.41M | ﹤0.01% |
76,943
-720,043
| -90% | -$22.5M |
|
598
Procter & Gamble
PG
$370B
| $2.17M | ﹤0.01% |
13,636
+3,016
| +28% | +$481K |
|
599
Penumbra
PEN
$10.5B
| $2.04M | ﹤0.01% |
7,945
-625,663
| -99% | -$161M |
|
600
Antero Resources
AR
$9.92B
| $1.97M | ﹤0.01% |
48,839
-1,323,450
| -96% | -$53.3M |
|